相似文献
1
Coming of age: the use of immunomodulatory therapy in children with multiple sclerosis.
Neurology. 2005 Mar 8;64(5):778-9. doi: 10.1212/01.WNL.0000153532.80277.21.
2
Use of interferon-beta in the treatment of multiple sclerosis.
Adv Neurol. 2006;98:257-71.
3
Interferon neutralizing antibodies in multiple sclerosis: a new perspective.
Arch Neurol. 2010 Apr;67(4):386-7. doi: 10.1001/archneurol.2010.31.
4
Defining multiple sclerosis treatment response with magnetic resonance imaging: how much activity is too much?
Arch Neurol. 2009 Jan;66(1):19-20. doi: 10.1001/archneurol.2008.529.
5
Translating new insights into treatment optimisation in multiple sclerosis.
J Neurol Sci. 2009 Feb 1;277 Suppl 1:S1-2. doi: 10.1016/S0022-510X(09)70002-4.
6
Confounders in natural history of interferon-beta-treated relapsing multiple sclerosis.
Ann Neurol. 2008 Jan;63(1):126; author reply 126-7. doi: 10.1002/ana.21186.
7
The use of glatiramer acetate in the treatment of multiple sclerosis.
Adv Neurol. 2006;98:273-92.
8
Seeing injectable MS therapies differently: they are more similar than different.
Neurology. 2009 Jun 9;72(23):1972-3. doi: 10.1212/WNL.0b013e3181a92c82. Epub 2009 May 13.
9
Interferon-beta and neuroprotection in multiple sclerosis--facts, hopes and phantasies.
Exp Neurol. 2007 Jan;203(1):1-4. doi: 10.1016/j.expneurol.2006.09.007. Epub 2006 Oct 25.
10
A practical approach to immunomodulatory therapy for multiple sclerosis.
Phys Med Rehabil Clin N Am. 2005 May;16(2):449-66, ix. doi: 10.1016/j.pmr.2005.01.007.
引用本文的文献
1
Therapies for multiple sclerosis: considerations in the pediatric patient.
Nat Rev Neurol. 2011 Feb;7(2):109-22. doi: 10.1038/nrneurol.2010.198. Epub 2011 Jan 11.
Zotero 插件